The scientific cooperation between VERTEX and Almazov Centre includes the development of the composition and dosage form, patenting, preclinical, clinical and other laboratory studies, the registration of drugs and the elaboration of technology in production.
The new drug compositions are formulated with modern substances that have proven to be effective and safe for the treatment of arterial hypertension. The development costs are estimated at about RUB 70 mln, the project period is up to 10 years. According to experts in pharmacy and medicine, combined drugs that contain four ingredients for the treatment of arterial hypertension are the future of modern cardiology. The parties intend to cooperate and develop the medicines of this type.
CVD control is one of the major federal projects of the National Healthcare Project until 2024. The scientific cooperation between VERTEX and Almazov Centre will contribute to reducing mortality and meeting the priority objective of increasing the life expectancy up to 80 years, fulfilling the tasks of the Russian health care system, and increasing the effectiveness of treatment methods.
“This project will provide patients with modern medicines and improve the treatment of arterial hypertension, and new drugs will be included in the relevant treatment standards for this purpose,” commented Prof. Evgeny Shlyakhto, Director General of Almazov Centre.
Director General of Vertex Georgy Pobelyansky thanked Evgeny Shlyakhto for his trust and expressed hope for further fruitful cooperation.